Trial Profile

Phase I study of benzhydrocodone [KemPharm] in volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benzhydrocodone (Primary) ; Hydrocodone/paracetamol
Indications Acute pain
Focus Pharmacokinetics; Registrational

Most Recent Events

22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
19 Nov 2012 Based on results of this trial, KemPharm receives positive feedback from the US FDA on further clinical studies required for the approval of KP 201 under the 505(b)(2) regulatory pathway, according to a company media release.
22 May 2012 Status changed from recruiting to completed, according to a KemPharm media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com